AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Up 0.4 %

Shares of AbbVie stock traded up $0.52 on Friday, hitting $142.60. 5,208,659 shares of the company traded hands, compared to its average volume of 5,923,121. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91. The company has a quick ratio of 0.75, a current ratio of 0.84 and a debt-to-equity ratio of 4.15. The company has a market cap of $252.13 billion, a PE ratio of 20.20, a PEG ratio of 3.99 and a beta of 0.70. The company has a 50-day moving average price of $146.89 and a 200 day moving average price of $150.34.

AbbVie (NYSE:ABBV - Get Rating) last issued its earnings results on Friday, July 29th. The company reported $3.51 EPS for the quarter, beating analysts' consensus estimates of $3.42 by $0.09. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. The firm had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $14.64 billion. During the same quarter in the previous year, the company posted $3.11 earnings per share. The business's quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts predict that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be paid a $1.41 dividend. This represents a $5.64 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend is Thursday, July 14th. AbbVie's dividend payout ratio (DPR) is presently 79.89%.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Morgan Stanley reduced their target price on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating for the company in a report on Monday, August 1st. SVB Leerink initiated coverage on AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 target price on the stock. Atlantic Securities reduced their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a report on Monday, August 1st. BMO Capital Markets lifted their price target on AbbVie from $161.00 to $174.00 and gave the stock an "outperform" rating in a research note on Monday, April 25th. Finally, Wells Fargo & Company upped their price objective on shares of AbbVie from $165.00 to $200.00 in a research note on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $159.63.

Insiders Place Their Bets

In related news, Vice Chairman Michael Severino sold 79,801 shares of AbbVie stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total value of $12,041,970.90. Following the completion of the sale, the insider now owns 152,103 shares of the company's stock, valued at approximately $22,952,342.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Vice Chairman Michael Severino sold 79,801 shares of the stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the transaction, the insider now owns 152,103 shares of the company's stock, valued at approximately $22,952,342.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Henry O. Gosebruch sold 83,960 shares of the business's stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $155.00, for a total value of $13,013,800.00. Following the completion of the sale, the executive vice president now owns 16,623 shares of the company's stock, valued at $2,576,565. The disclosure for this sale can be found here. Insiders sold 263,761 shares of company stock valued at $40,500,771 over the last ninety days. Corporate insiders own 0.08% of the company's stock.